Sparking gains in Irish biotech firm Amarin (AMRN +8.6%) is a Leerink Swann note speculating...
Thursday, March 15, 2012, 12:26 PM ETSparking gains in Irish biotech firm Amarin (AMRN +8.6%) is a Leerink Swann note speculating that "patent progress could solidify Amarin as a prime takeout candidate given the blockbuster potential for [heart-drug candidate] AMR-101." The firm had earlier said AMRN was moving toward winning its quest for U.S. patent protection for AMR-101.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles